Anti-fibrotic sialidase inhibitor compounds and methods of use
AssigneeThe Texas A&M University System
InventorsRichard H. Gomer, Darrell Pilling, Nehemiah Cox, Tejas R. Karhadkar
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to anti-fibrotic sialidase-inhibitor compounds and methods of preventing or inhibiting fibrosis using such compounds. The present disclosure also relates to methods of controlling the formation of fibrocytes or their activity using such compounds. The compounds may include both antibodies as well as small molecules. The methods may involve administering the compounds to a patient with or at risk of developing fibrosis in a manner that inhibits at least one sialidase in the patient.
Claims20
1-32. (canceled)
A method of preventing or inhibiting fibrosis in a human comprising administering to a human at least one of Compounds 4-8, Compound 25, or any combination thereof, in an amount and for a time sufficient to inhibit the activity of at least one human sialidase in the human to prevent or inhibit fibrosis resulting from pulmonary interstitial fibrosis.
A method of preventing or inhibiting fibrosis in a human comprising administering to a human, at least one of Compounds 4-8 or Compound 25, or any combination thereof, in an amount and for a time sufficient to inhibit the activity of at least two human sialidases in the human to prevent or inhibit fibrosis resulting from pulmonary interstitial fibrosis.
A method of preventing or inhibiting fibrosis in a human comprising administering to a human at least one of Compounds 4-8, Compound 25, or any combination thereof, in an amount and for a time sufficient to inhibit level or activity of TGF-β1 in the human.
Dependencies are inferred from the claim text.